A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Triamcinolone (Primary) ; Triamcinolone
- Indications Osteoarthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Flexion Therapeutics
- 13 Dec 2017 New trial record
- 07 Dec 2017 According to a Flexion Therapeutics media release, the first patient has been enrolled in this trial.
- 07 Dec 2017 According to a Flexion Therapeutics media release, the company expects to report top-line results from this trial in the first half of 2018.